C4 Therapeutics (CCCC) Proxy filing summary

Executive summary

• Advanced clinical pipeline by prioritizing cemsidomide for multiple myeloma, supported by compelling Phase 1 data and a differentiated safety profile; initiated Phase 2 and 1b trials, including collaborations with Pfizer.

• Implemented a new discovery strategy focused on inflammation, neuroinflammation, and neurodegeneration, leveraging a decade of expertise in targeted protein degradation.

• Strengthened financial position with a $125 million financing, extending cash runway through 2028 and supporting ambitious milestones through 2026–2028.

• Achieved key milestones in discovery collaborations with Biogen, Roche, and Merck KGaA, including advancing candidates into clinical development.

Voting matters and shareholder proposals

• Four proposals to be voted: election of three Class III directors, advisory vote on executive compensation, ratification of KPMG LLP as auditor, and amendment to the 2020 Stock Option and Incentive Plan to include pre-funded warrants in the evergreen provision.

• Board recommends voting FOR all proposals.

• Shareholders of record as of April 27, 2026, are entitled to vote; voting can be done online, by phone, or by mail.

Board of directors and corporate governance

• Board consists of ten members divided into three staggered classes; majority are independent directors.

• Board committees include Audit, Organization, Leadership and Compensation (OLCC), Nominating and Corporate Governance (NCGC), and Science and Technology.

• Board and committees met regularly, with high attendance; annual self-evaluations and succession planning are in place.

• Board diversity in skills, experience, and backgrounds is emphasized.